Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: Findings in EUROASPIRE II

Atherosclerosis Supplements

Volumn 2, Issue 4, 2002, Pages 13-17

  De Backer, Guy ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Atherosclerotic disease; Coronary heart disease; EUROASPIRE

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ATHEROSCLEROSIS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL PRACTICE; CONFERENCE PAPER; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HEART FAILURE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; PATIENT; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; THROMBOEMBOLISM; ACHIEVEMENT; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; EUROPE; HEALTH BEHAVIOR; MOTIVATION; REVIEW;

ACHIEVEMENT; CORONARY DISEASE; EUROPE; EVIDENCE-BASED MEDICINE; GOALS; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; RECURRENCE; RISK FACTORS;

EID: 1242273622     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00017-4     Document Type: Conference Paper

References (8)

1. Wood D., De Backer G., Faergeman O., Graham I., Mancia G., Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur. Heart J. 19:1998;1434-1503.
2. A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events). Heart. 75:1996;334-342.
3. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur. Heart J. 18:1997;1569-1582.
4. Graille V., Ferrières J., Marques-Vidal P., Riudavets J.B., Rodier P., Cambou J.P. Long-term effects of prescription drugs in 174 patients treated for myocardial infarction, followed up from 4 to 5 years (the DEVENIR study). Arch. Mal. Cœur. Vaiss. 89:1996;35-39.
5. de Velasco J.A., Cosin J., Lopez Sendon J.L., de Teresa E., de Oya M., Carrasco J.L., Navarro A. Secondary prevention of myocardial infarction in Spain: the PREVERSE Study. Rev. Esp. Cardiol. 50:1997;406-415.
6. Pyörälä K., De Backer G., Graham I., Poole-Wilson P.A., Wood D.A. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 15:1994;1300-1331.
7. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey Programme. Eur. Heart J. 22:2001;554-572.
8. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Lancet. 357:2001;995-1001.